| ¿µ¹® | asphycitic syndrome | ÇÑ±Û | Áú½ÄÁõÈıº |
|---|---|---|---|
| ¼³¸í | È£Èí±âÁßÀÇ »ê¼Ò°áÇÌ¿¡ ÀÇÇÑ »ý¸íÁ¤ÁöÀÇ Àý¹ÚÇÑ »óÅÂ, ¶Ç´Â ½ÇÁ¦·Î Á¤Áö°¡ ÀÏ¾î³ »óÅÂ, °íÀÌ»êÈź¼ÒÁõ°ú Àú»ê¼ÒÁõ ȤÀº ¹«»ê¼ÒÁõ µîÀÌ µ¿¹ÝµÈ´Ù. ¿Ü°è ÆóÀÇ °íÅëÀÌ µÎÀýµÇ¾î ÆóÀÇ È£ÈíÀÛ¿ëÀÌ Àå¾ÖµÇ´Â °Í(¿ÜÁú½Ä)°ú °¡½º³ª ¾àÁ¦¿¡ ÀÇÇØ »ýü³» Á¶Á÷ÀÇ °¡½º±³È¯ÀÌ ¹æÇظ¦ ¹Þ´Â °Í(³»Áú½Ä)ÀÌ ÀÖ´Ù. ÀϹÝÀûÀ¸·Î ¿ÜÁú½ÄÀ» °¡¸®Å°´Â °æ¿ì°¡ ¸¹´Ù. ¿øÀÎÀ¸·Î¼´Â ÄÚ³ª ÀÔ µî È£ÈíÀÔ±¸ÀÇ Æó»ö, À½½Ä¹°À̳ª À̹°¿¡ ÀÇÇÑ ±âµµÆó»ö, ¸ñÁ¶ÀÓ, ¹° ¶Ç´Â ºÐºñ¹° µîÀÌ ±âµµ·Î µé¾î°¡´Â °Í, ¾à¹° ¶Ç´Â ÆÄ»ódz¿¡ ÀÇÇÑ È£Èí±Ù¸¶ºñ, ¸Å¸ô µî ¿Ü·Â¿¡ ÀÇÇÑ È£Èí¿îµ¿ÀÇ ÀúÁö, °ø±â ÁßÀÇ »ê¼ÒºÎÁ· ¹× À¯µ¶°¡½ºÀÇ ÈíÀÔ µîÀ» µé ¼ö ÀÖ´Ù. |
||
| ¿µ¹® | nephrotic syndrome | ÇÑ±Û | ÄáÆÏÁõÈıº |
|---|---|---|---|
| ¼³¸í | ÄáÆÏÀÇ Å丮ÀÌ»ó¿¡ ÀÇÇÑ ´Ü¹éÁú¼Õ½ÇÀÌ ÁÖ¿øÀÎÀÎ º´ÀÌ´Ù. ±× Á¤ÀÇ´Â ¼ºÀÎÀÇ ¿ä´Ü¹é·®(¼Òº¯¿¡ ¼¯¿© ³ª¿À´Â ´Ü¹éÁúÀÇ ¾ç. ´ë°³ Á¤»óÀο¡¼´Â ³ª¿ÀÁö ¾Ê°Å³ª, ȤÀº ¾ÆÁÖ ¼Ò·®ÀÌ ³ª¿Ã »ÓÀÓ)ÀÌ ÇÏ·ç 3.5mgÀÌ»ó, ¶ÇÇÑ ¼Ò¾Æ¿¡¼´Â Ç÷Áß ¾ËºÎ¹Î³óµµ°¡ 2.5mgÀÌÇÏ, ÇÏ·íµ¿¾È ¼Òº¯À¸·Î ³ª¿À´Â ¿ä´Ü¹é·®À» ½Ã°£´ç °è»êÇßÀ» ¶§ ½Ã°£´ç 40mgÀÌ»óÀÎ °æ¿ìÀÌ´Ù. µû¶ó¼ ÄáÆÏÁõÈıºÀ̶õ À§ÀÇ Á¤ÀÇ¿¡ ÇÕ´çÇϱ⸸ ÇÏ¸é ¸ðµÎ ÇØ´çµÇ¹Ç·Î, ¿©·¯ °¡Áö ¿øÀο¡ ÀÇÇÑ ÄáÆÏÀÌ»óÀ¸·Î¼ ´Ü¹éÁúÀÇ Áö³ªÄ£ ¹èÃâÀ» ³ªÅ¸³»´Â Áúº´ÀÇ ÁýÇÕü¸¦ ¶æÇÑ´Ù. ´ë°³ Áõ»óÀº Áö³ªÄ£ Ç÷ÁߴܹéÁúÀÇ °¨¼Ò·Î ÀÎÇÑ ºÎÁ¾, ±×¸®°í ÀÌÂ÷ÀûÀÎ Áõ»óÀ¸·Î ¹ß»ýÇÑ °íÁöÁúÇ÷Áõ, °¨¿°°¨¼ö¼ºÀÇ Áõ°¡, °íÇ÷¾Ð µîÀÌ´Ù. Ä¡·á¿Í ¿¹ÈÄ´Â ÄáÆÏÁõÈıºÀ» ³ªÅ¸³»´Â °¢ ¿øÀο¡ µû¶ó ´Ù¸£³ª, ´ë°³ ¼Ò¾Æ¿¡ ¹ß»ýÇÑ °æ¿ì ½ºÅ×·ÎÀ̵åÁ¦Àç¿¡ ÀÇÇÑ Ä¡·áÈ¿°ú°¡ ³ô´Ù. |
||
| ¿µ¹® | Cushing's syndrome | ÇÑ±Û | Äí½ÌÁõÈıº |
|---|---|---|---|
| ¼³¸í | Äí½ÌÁõÈıºÀ̶õ ±Û·çÄÚÄÚ¸£Æ¼ÄÚÀ̵尡 ¸¸¼ºÀûÀ¸·Î °úÀ׺кñ¿¡ ÀÇÇØ¼ ÀϾ´Â º´À» ¸»ÇÑ´Ù. ¿øÀÎÀ¸·Î ¨ç ³úÇϼöü¿¡¼ ACTH°¡ °úÀ× ºÐºñµÇ´Â °æ¿ì: ³úÇϼöü¿¡¼ ACTH°¡ ³Ê¹«³ª ¸¹ÀÌ ºÐºñµÇ´Â °æ¿ì¿¡ ºÎ½Å°ÑÁúÀ» ÀÚ±ØÇؼ ¸¹Àº ¾çÀÇ ±Û·çÄÚÄÚ¸£Æ¼ÄÚÀ̵尡 ºÐºñµÈ´Ù. ¨è ³úÇϼöü ÀÌ¿ÜÀÇ ºÎºÐ¿¡¼ ACTH°¡ ¸¹ÀÌ ºÐºñµÇ´Â °æ¿ì: Æó¾Ï, ³¼Ò¾Ï µîÀÇ Á¾¾ç¿¡¼ ACTH¸¦ »ý»êÇÏ´Â °æ¿ì°¡ ÀÖ´Ù. ÀÌ °æ¿ì¿¡µµ ¿ª½Ã ºÎ½ÅÇÇÁúÀÌ ÀÚ±ØÀÌ µÇ¾î¼ ¸¹Àº ¾çÀÇ ±Û·çÄÚÄÚ¸£Æ¼ÄÚÀ̵尡 ºÐºñµÈ´Ù. ¨é ACTHÀÇ ÀÚ±ØÀÌ ¾øÀÌ ºÎ½Å¿¡¼ ¸¹Àº ¾çÀÇ ±Û·çÄÚÄÚ¸£Æ¼ÄÚÀ̵尡 ³ª¿À´Â °æ¿ì. ACTHÀڱؿ¡ °ü°è¾øÀÌ ºÎ½ÅÇÇÁúÀÇ °úÀ×¼ºÀå, Á¾¾ç¿¡ ÀÇÇØ¼ ¸¹Àº ¾çÀÇ ±Û·çÄÚÄÚ¸£Æ¼ÄÚÀ̵尡 ºÐºñµÇ´Â °æ¿ì. ¨ê ¿ÜÀμº, ÀÇÀμº: Ä¡·á¸¦ À§Çؼ ¸¹Àº ¾çÀÇ ±Û·çÄÚÄÚ¸£Æ¼ÄÚÀ̵带 Àå±â Åõ¿©ÇÒ °æ¿ì¿¡ »ý±â´Â Äí½ÌÁõÈıº Äí½ÌÁõÈıº¿¡¼ ƯÈ÷ ¨ç¹ø¿¡ ÇØ´çÇÏ´Â °ÍÀ» Äí½Ìº´¶ó°í ÇÑ´Ù. Áõ»óÀº ¶×¶×ÇÏ°í ¾ó±¼ÀÌ ´Þµ¢ÀÌó·³ µÕ±Û°í »ìÀÌ ÂÈÁö¸¸ ÆÈ, ´Ù¸®´Â °¡´Ã°í ´ë½Å¿¡ ¸ö¿¡ ¸¹Àº »ìÀÌ ºÙ¾îÀÖ´Ù. ¸ñµÚ¿¡ ¸¹Àº »ìÀÌ ÀÖ¾î¼ ±×°ÍÀÌ µ¢¾î¸®¸¦ Çü¼ºÇϱ⵵ ÇÑ´Ù. À̰ÍÀº ¿ø·¡ ±Û·çÄÚÄÚ¸£Æ¼ÄÚÀ̵尡 Áö¹æÀ» ºÐÇØÇÏ´Â ¿ªÇÒÀ» ÇÏÁö¸¸ º´ÀûÀ¸·Î ¸¹ÀÌ ³ª¿Ã °æ¿ì¿¡´Â Áö¹æÀÇ ºÐÆ÷¸¦ º¯È½ÃŰ´Â ¿ªÇÒÀ» Çϱ⠶§¹®ÀÌ´Ù. Áï ÆÈ, ´Ù¸® µîÀÇ ¿Â¸ö¿¡ ÆÛÁ®ÀÖ´Â Áö¹æÀ» ¸öÅëÂÊÀ¸·Î ¸ðµÎ À̵¿½ÃŲ´Ù. ÀÜÅÐÀÌ ¿Â¸ö¿¡ °ÉÃļ ¸¹ÀÌ ³ªÀÖ°í ¿©µå¸§ÀÌ ¸¹°í ¹è¿¡ ÀÚÁÖ»ö ¼±Á¶°¡ ÀÖ´Â °æ¿ì°¡ ¸¹´Ù. ±×¸®°í ±Û·çÄÚÄÚ¸£Æ¼ÄÚÀ̵尡 ´Ü¹éÁúÀ» ºÐÇØÇØ¼ ´ç·ù¸¦ ¸¸µå´Â ¿ªÇÒÀ» ÇÏ¿© ±ÙÀ°À̳ª »À´ëÀÇ ½ÉÇÑ ¼Ò½ÇÀÌ ÀÖ´Ù. ±×·¡¼ ±ÙÀ°ÀÌ °ÅÀÇ ¾ø¾îÁö°í »À´Â ¾ÆÁÖ ºÎ·¯Áö±â ½±°Ô µÈ´Ù. ´ë°³ °íÇ÷¾ÐÀÎ °æ¿ì°¡ ¸¹°í ½É¸®ÀûÀ¸·Î ¿ì¿ïÁõÀ̳ª °ú¹Î¼º µîÀÌ ÀÖÀ» ¼öµµ ÀÖ°í ½ÉÇÑ °æ¿ì¿¡´Â Á¤½Åº´Áõ¼¼¸¦ º¸À̱⵵ ÇÑ´Ù. |
||
| ¿µ¹® | Klinefelter syndrome | ÇÑ±Û | Ŭ¶óÀÎÆçÅÍÁõÈıº |
|---|---|---|---|
| ¼³¸í | 1942³â H.F. Ŭ¶óÀÎÆçÅͰ¡ ±âÀçÇÑ ¼º¿°»öüÀÌ»óÁõÈıº. Á¤»óÀÎÀÇ ¼º¿°»öüÇüÀº ³²¼º XY, ¿©¼º XX¸¦ ³ªÅ¸³»Áö¸¸, ÀÌ ÁõÈıº¿¡¼´Â ¼º¿°»öüÇüÀÌ XXY. XXYY, XXXXY µîÀÇ ¿©·¯ °¡Áö ÀÌ»óÇÑ ÇüŸ¦ ³ªÅ¸³½´Ù. ¿Ü¼º±â-ü°Ý-¼ºÂ¡ µîÀÇ Æ¯Â¡ÀûÀÎ Áõ¼¼·Î º¼ ¶§¿¡ ¿ÏÀüÇÑ ³²¼ºÀÌ °áÈ¥ÇÏ¿© ¼º»ýȰ±îÁö ÇÏ¿´À¸³ª, ÀÚ½ÄÀÌ ¾øÀÚ ºÎºÎ°¡ ÇÔ²² º´¿øÀ» ã¾Æ°¡¼ ¿°»öü¸¦ °Ë»çÇØ º¸°í ³²ÀÚ¿¡°Ô ÀÌ ÁõÈıºÀÌ ÀÖÀ½À» ¾Ë°Ô µÇ´Â °æ¿ì°¡ ¸¹´Ù. ÀÌ ¹Û¿¡ ¼ºÀÎÀÌ µÇ¾î ³ªÅ¸³ª´Â ÁÖ¿ä Áõ¼¼¸¦ µé¸é, ÀÛÀº°íȯ, ¿©¼ºÇü À¯¹æÁõ, ¹«Á¤ÀÚÁõ, ºÒÀÓ, ¿äÁß °í³ªµµÆ®·ÎÇÉÀÇ »ó½Â, Áö´É ÀúÇÏ µîÀÌ´Ù. Ä¡·á´Â 2Â÷ ¼ºÂ¡ÀÇ ÃËÁøÀ» À§ÇÏ¿© È£¸£¸ó¿ä¹ý¿¡ ÀÇÇÑ ³²¼ºÈ¸¦ ½ÃµµÇÑ´Ù. |
||
| ¿µ¹® | fetal alcohol syndrome | ÇÑ±Û | žƾËÄÚ¿ÃÁõÈıº |
|---|---|---|---|
| ¼³¸í | ÀӽűⰣ Áß ¸¸¼ºÀûÀ¸·Î ¾ËÄÚ¿ÃÀ» ¼·ÃëÇÑ ¿©ÀÚ¿¡°Ô¼ ÅÂ¾î³ ¿µ¾Æ¿¡°Ô ³ªÅ¸³ª´Â ÇüŹ߻ýÀÇ ÀÌ»óÀ» ³ªÅ¸³»´Â ÁõÈıºÀ¸·Î¼ À§ÅλÀ¹ßÀ°ºÎÀü, ¾Õ¸Ó¸®¿Í ¾Æ·¡ÅÎÀÇ µ¹Ãâ, ªÀº°Ë¿, ÀÛÀº¾È±¸Áõ, ´«±¸¼®ÁÖ¸§, ½ÉÇÑ ¼ºÀåÁö¿¬, Á¤½ÅÁöü µîÀ» ³ªÅ¸³½´Ù. |
||
| PCS | palliative care service; Patient Care System; patterns of care study; pelvic congestion syndrome; ph... |
|---|---|
| AS | acetylstrophanthidin; acidified serum; acoustic schwannoma; acoustic stimulation; active sarcoidosis... |
| BS | Bachelor of Science; Bachelor of Surgery; Bacillus subtilis; Bartter syndrome; base strap; bedside; ... |
| SAS | sarcoma amplified sequence; self-rating anxiety scale; short arm splint; Sklar Aphasia Scale; sleep ... |
| DPS | delayed primary suture; descending perineum syndrome; dimethylpolysiloxane; dysesthetic pain syndrom... |
| sleep paralysis | <neurology, physiology> A condition that occurs in REM stage sleep. There is no movement of the skeletal muscles in this stage of sleep. See: REM stage sleep. (27 Sep 1997) |
|---|---|
| sleep, rem | A stage of sleep characterised by rapid movements of the eye and low voltage fast pattern eeg. It is usually associated with dreaming. (12 Dec 1998) |
| sleep spindle | The electroencephalographic record of 14-per-second bursts of wave frequency seen on EEG examination. (05 Mar 2000) |
| sleep stages | Periods of sleep manifested by changes in eeg activity and certain behavioural correlates; includes stage 1: sleep onset, drowsy sleep; stage 2: light sleep; stages 3 and 4: delta sleep, light sleep, deep sleep, telencephalic sleep. (12 Dec 1998) |
| sleep terror | A disorder allied to nightmare, occurring in children, in which the child awakes screaming with fright, the distress persisting for a time during a state of saemiconsciousness. Synonym: pavor nocturnus, sleep terror. (05 Mar 2000) |
| delta sleep-inducing peptide | <chemical> A nonapeptide that is found in neurons, peripheral organs, and plasma. This neuropeptide induces mainly delta sleep in mammals. In addition to sleep, the peptide has been observed to affect electrophysiological activity, neurotransmitter levels in the brain, circadian and locomotor patterns, hormonal levels, psychological performance, and the activity of neuropharmacological drugs including their withdrawal. Chemical name: Delta sleep-inducing peptide (12 Dec 1998) |
| obstructive sleep apnoea | A form of sleep apnoea which occurs as the result of a physical occlusion of the oropharyngeal airway during sleep. (27 Sep 1997) |
| electric sleep | A condition of convulsions and unconsciousness induced by the passage of an electric current through the brain. (05 Mar 2000) |
| electrotherapeutic sleep therapy | Treatment by inducing sleep by means of nonconvulsive electric stimulation of the brain. (05 Mar 2000) |
| twilight sleep | Formerly a method of producing sleep for delivery by a combination of morphine and scopolamine. (05 Mar 2000) |
| light sleep | A condition of half sleep. Synonym: light sleep. Origin: dys-+ G. Nystaxis, drowsiness (05 Mar 2000) |
| accelerated phase of leukaemia | Refers to chronic myelogenous leukaemia that is progressing. The number of immature, abnormal white blood cells in the bone marrow and blood is higher than in the chronic phase, but not as high as in the blast phase. (12 Dec 1998) |
| acceleration phase | <cell biology, cell culture> A period of increasing growth before the log phase in a culture of microbes. After the culture is started on a medium, at first there is no growth (the lag phase) and then the microbes start to gradually grow (acceleration phase) until they reach a constant maximum rate of growth (log phase). (15 Jan 1998) |
| acute-phase protein | <haematology> These plasma proteins (in addition to fibrinogen) increase 25% or more in response to inflammation and injury are under direct control of interleukin-6 (IL-6) (hepatocyte-stimulating factor). Other proteins which increase are ceruloplasmin, C3 and C4 which increase 50% or more; alpha-1 acid glycoprotein, alpha-1 antitrypsin, haptoglobin and fibrinogen (the major determinant of viscosity 1 ) which increase two- to fourfold; C-reactive protein (CRP) and serum amyloid A which increase several hundred-fold. Despite long-held clinical opinion to the contrary, available data indicate that neither ESR nor measurement of specific acute-phase reactants are useful in excluding underlying infection or inflammation regardless of the pretest probability. These proteins are secreted into the blood in increased or decreased quantities by hepatocytes in response to trauma, inflammation, or disease. They can serve as inhibitors or mediators of the inflammatory processes. Certain acute-phase proteins have been used to diagnose and follow the course of diseases or as tumour markers. See also: amyloid, c-reactive protein, erythrocyte sedimentation rate, viscosity. (25 Jun 1999) |
| acute-phase reaction | <immunology, rheumatology> Refers to the changes in synthesis of certain proteins within the serum during an inflammatory response, which provides rapid protection for the host against microorganisms via non-specific defense mechanisms. It consists of fever, an increase in inflammatory humoral factors, and an increased synthesis by hepatocytes of a number of proteins or glycoproteins usually found in the plasma; the reaction is mediated by endogenous pyrogens, the hypothalamus, adrenal hormones, and other factors. (12 Jul 2000) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|